1. Home
  2. ITRM vs MAIA Comparison

ITRM vs MAIA Comparison

Compare ITRM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • MAIA
  • Stock Information
  • Founded
  • ITRM 2015
  • MAIA 2018
  • Country
  • ITRM Ireland
  • MAIA United States
  • Employees
  • ITRM N/A
  • MAIA N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ITRM Health Care
  • MAIA Health Care
  • Exchange
  • ITRM Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • ITRM 49.5M
  • MAIA 52.8M
  • IPO Year
  • ITRM 2018
  • MAIA 2022
  • Fundamental
  • Price
  • ITRM $1.54
  • MAIA $2.00
  • Analyst Decision
  • ITRM Strong Buy
  • MAIA
  • Analyst Count
  • ITRM 1
  • MAIA 0
  • Target Price
  • ITRM $5.00
  • MAIA N/A
  • AVG Volume (30 Days)
  • ITRM 671.4K
  • MAIA 346.7K
  • Earning Date
  • ITRM 11-14-2024
  • MAIA 11-12-2024
  • Dividend Yield
  • ITRM N/A
  • MAIA N/A
  • EPS Growth
  • ITRM N/A
  • MAIA N/A
  • EPS
  • ITRM N/A
  • MAIA N/A
  • Revenue
  • ITRM N/A
  • MAIA N/A
  • Revenue This Year
  • ITRM N/A
  • MAIA N/A
  • Revenue Next Year
  • ITRM N/A
  • MAIA N/A
  • P/E Ratio
  • ITRM N/A
  • MAIA N/A
  • Revenue Growth
  • ITRM N/A
  • MAIA N/A
  • 52 Week Low
  • ITRM $0.81
  • MAIA $1.17
  • 52 Week High
  • ITRM $3.02
  • MAIA $5.99
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 39.39
  • MAIA 44.72
  • Support Level
  • ITRM $1.58
  • MAIA $1.97
  • Resistance Level
  • ITRM $2.10
  • MAIA $2.44
  • Average True Range (ATR)
  • ITRM 0.14
  • MAIA 0.20
  • MACD
  • ITRM -0.04
  • MAIA 0.00
  • Stochastic Oscillator
  • ITRM 11.11
  • MAIA 8.33

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Share on Social Networks: